Survodutide

Survodutide, identified in the scientific literature by its development code BI 456906, is an investigational once-weekly injectable peptide designed to activate two different receptors: the glucagon receptor (GCGR) and the glucagon-like peptide-1 receptor (GLP-1R). Molecules of this type are often called dual agonists or, informally, twincretins.

The compound originated in a research collaboration between Zealand Pharma and Boehringer Ingelheim. Boehringer Ingelheim leads global clinical development and would be responsible for any future commercialization, while Zealand Pharma retains an economic interest in the program. That partnership structure explains why announcements about survodutide typically appear from both companies on the same day.

Chemically, survodutide is an acylated glucagon analogue rather than an analogue of oxyntomodulin, which distinguishes it from several competing dual agonists. It is built on a 29-amino-acid backbone and carries a fatty acid side chain that binds reversibly to albumin, slowing clearance enough to support weekly subcutaneous administration. Reference databases list a molecular formula of C₁₉₂H₂₈₉N₄₇O₆₁ and a molecular weight near 4,232 g/mol, though values reported by chemical suppliers vary with salt form and with the convention used to count the acyl chain.

Two points of context matter before reading any efficacy number. First, survodutide has no marketing authorization anywhere in the world. Every result discussed below comes from a clinical trial conducted under regulatory oversight, with medical monitoring, protocol-defined dose escalation and laboratory surveillance that no individual can reproduce outside a trial. Second, survodutide sits inside a crowded field of next-generation incretin-based molecules, and its scientific interest lies less in raw weight loss than in what the glucagon arm adds. For the wider pharmacological landscape, see our overview of next-generation GLP-1 and incretin therapies.

Medical disclaimer: this guide is educational. It is not medical advice, and nothing here should be read as encouragement to obtain or use an unapproved compound. Consult a qualified healthcare professional for any question about obesity, diabetes or liver disease.

The GLP-1 arm of survodutide is the familiar one. GLP-1 receptor activation slows gastric emptying, enhances glucose-dependent insulin secretion and acts on hypothalamic and brainstem circuits that regulate appetite and satiety. Most of the appetite suppression and most of the gastrointestinal side effects of the drug class trace back to this pathway.

The glucagon arm is what makes survodutide pharmacologically distinctive. Glucagon is usually discussed as the hormone that raises blood glucose by stimulating hepatic glycogenolysis and gluconeogenesis, which sounds like the opposite of what a metabolic drug should do. But sustained glucagon receptor agonism also increases energy expenditure and promotes hepatic fatty acid oxidation and lipolysis. The design logic of a dual agonist is that the GLP-1 component restrains food intake and offsets the glycemic effect of glucagon, while the glucagon component adds an energy-output and liver-directed effect that GLP-1 alone does not provide.

That balance is a pharmacological tightrope. Too much glucagon agonism relative to GLP-1 risks worsening glycemic control; too little erases the metabolic advantage. Survodutide was engineered to weight these activities in a specific ratio, and the trial program is in effect a test of whether that ratio translates into clinical benefit in humans.

There is now human evidence that part of the liver effect is not simply a consequence of weight loss. A mediation analysis published in Hepatology in 2026, using 170 participants with stage F2 to F3 fibrosis and paired liver biopsies from the phase 2 MASH trial, estimated that weight reduction accounted for roughly 72% of the treatment effect on improvement in MASH but only about 36% of the effect on fibrosis improvement. For biomarkers of inflammation and fibrosis, the proportion attributable to weight loss was lower still, between about 17% for AST and 39% for the Enhanced Liver Fibrosis test. Mediation analyses are post hoc and model-dependent, so these figures are indicative rather than definitive, but they are consistent with a weight-independent hepatic mechanism.

Pharmacokinetically, survodutide was administered once weekly by subcutaneous injection in all pivotal trials, following protocol-defined gradual dose escalation. The trials used escalation schedules precisely because tolerability depends on them, which is one reason trial doses cannot be translated into any at-home regimen.

The pivotal dose-finding study was published in The Lancet Diabetes & Endocrinology in March 2024 by le Roux and colleagues. It was a randomised, double-blind, placebo-controlled trial in 387 adults with a body mass index of at least 27 kg/m² and without diabetes. Participants received placebo or one of four survodutide dose levels, administered once weekly for 46 weeks: a 20-week rapid escalation phase with increases every two weeks, followed by a 26-week maintenance phase.

At the highest dose studied, mean body weight fell by 14.9% compared with 2.8% with placebo. More than half of the participants in that group lost at least 15% of their body weight. The response was dose-dependent across the four dose levels, which is exactly what a dose-finding trial is designed to establish, and it was this gradient that defined the doses carried into phase 3.

Two caveats belong next to that headline. First, the rapid escalation schedule, with dose increases every two weeks, was aggressive by current standards, and the investigators themselves noted that a slower escalation might reduce dropout. Second, 24.6% of survodutide-treated participants discontinued because of adverse events, versus 3.9% on placebo, with most discontinuations clustered in the escalation phase. A result achieved in a trial where a quarter of the active group stopped early is a result that depends heavily on how the statistical analysis handles those missing data.

A separate 16-week phase 2 trial in people with type 2 diabetes, published by Blüher and colleagues in 2024, tested survodutide against both placebo and an open-label semaglutide arm. Body weight fell dose-dependently by up to 8.7%, and HbA1c improved. Weight reduction with the higher survodutide doses was numerically greater than with the open-label semaglutide comparator, but an open-label arm in a 16-week dose-ranging study is not a formal head-to-head comparison and should not be read as one. Adverse events were reported by 77.8% of survodutide-treated participants, mostly gastrointestinal, compared with 52.5% on placebo and 52.0% on semaglutide.

SYNCHRONIZE is the umbrella name for Boehringer Ingelheim's phase 3 program in obesity. Its two core trials, SYNCHRONIZE-1 and SYNCHRONIZE-2, were designed in parallel: both run for 76 weeks, both randomise participants to weekly survodutide titrated to 3.6 mg or 6.0 mg or to placebo, and both use co-primary endpoints of percentage change in body weight and the proportion of participants losing at least 5% of body weight.

SYNCHRONIZE-1 enrolled 725 adults with obesity or overweight and without type 2 diabetes (241, 242 and 242 participants in the 3.6 mg, 6.0 mg and placebo groups; mean age 47.1 years; 40.6% men) and was published in the New England Journal of Medicine in 2026. At week 76, mean body weight change was -12.2% at 3.6 mg, -13.0% at 6.0 mg and -5.4% with placebo, with at least 5% weight reduction in 72.6%, 71.9% and 46.3% of participants respectively. Under the sponsor's efficacy analysis, which estimates what happens in participants who stay on treatment as planned, the figures were up to 16.6% versus 3.2% with placebo, with at least 5% reduction in up to 85.1% versus 38.8%. The gap between the two sets of numbers is not a contradiction; it is the difference between asking what happens to everyone randomised and what happens to those who complete treatment as assigned. Readers comparing drugs should always check which analysis a number comes from.

SYNCHRONIZE-2 studied 755 adults with obesity and type 2 diabetes and was published in the New England Journal of Medicine on October 1, 2026, with results presented at the EASD annual meeting the same day. Body weight fell by up to 13.1% versus 3.1% with placebo at 76 weeks. From a mean baseline HbA1c of 7.4%, HbA1c fell by up to 1.21 percentage points versus 0.03 with placebo, and up to 29.5% of treated participants reached an HbA1c below 5.7% versus 4.0% on placebo. Weight loss is consistently smaller in people with type 2 diabetes across this entire drug class, so the lower figure is expected rather than anomalous.

The program extends well beyond these two trials. SYNCHRONIZE-CVOT is an event-driven cardiovascular safety trial in adults with a BMI of at least 27 kg/m² who have established cardiovascular disease, chronic kidney disease or multiple risk factors, randomised 1:1:1 to 3.6 mg, 6.0 mg or placebo, with a primary endpoint combining cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, ischemia-driven coronary revascularization and heart failure events. Its baseline characteristics report describes a cohort of roughly 5,500 randomised participants across 34 countries. Outcome results had not been published as of October 2026. Additional trials include SYNCHRONIZE-MASLD in fatty liver disease and SYNCHRONIZE-CN in Chinese adults.

The liver program is arguably the more scientifically interesting half of the survodutide story, because it is where the glucagon component is expected to contribute most.

The phase 2 liver trial, published by Sanyal and colleagues in the New England Journal of Medicine in July 2024, enrolled adults with biopsy-confirmed MASH and fibrosis stage F1 to F3. A total of 293 participants received at least one dose of survodutide (2.4 mg, 4.8 mg or 6.0 mg weekly) or placebo over 48 weeks, comprising 24 weeks of rapid escalation and 24 weeks of maintenance. The primary endpoint, biopsy-confirmed improvement in MASH with no worsening of fibrosis, was met by 47% of the 2.4 mg group, 62% of the 4.8 mg group and 43% of the 6.0 mg group, versus 14% with placebo.

Note that the response was not monotonic: the middle dose outperformed the highest dose. With roughly 73 participants per arm, that pattern is most plausibly explained by sample size and by tolerability-driven dropout at the top dose rather than by a true ceiling effect, but it is a reason to treat the 62% figure as the upper end of a noisy range. Secondary endpoints pointed in the same direction: a reduction of at least 30% in liver fat content occurred in 63%, 67% and 57% of the survodutide groups versus 14% with placebo, and improvement in fibrosis by at least one stage occurred in 34% to 36% of survodutide groups versus 22% with placebo. That fibrosis signal was a secondary endpoint and is hypothesis-generating rather than confirmatory.

These data earned survodutide Breakthrough Therapy designation from the US FDA in 2024 for adults with non-cirrhotic MASH and moderate or advanced fibrosis, and they supported two large phase 3 liver trials. LIVERAGE plans to enrol roughly 1,800 adults with MASH and stage F2 to F3 fibrosis, assessing MASH resolution and fibrosis improvement at 52 weeks before continuing for approximately seven years to measure progression to end-stage liver disease. LIVERAGE-Cirrhosis plans to enrol roughly 1,590 adults with compensated MASH cirrhosis over about four and a half years, with a primary endpoint of time to all-cause mortality or liver-related events.

In the meantime, the phase 3 SYNCHRONIZE-MASLD trial reported 48-week results in Nature Medicine in 2026. In 218 adults with obesity and metabolic dysfunction-associated steatotic liver disease, up to 84.2% of survodutide-treated participants achieved at least a 30% relative reduction in liver fat versus 24.3% with placebo, and relative body weight reduction reached up to 12.2% versus 1.0%. A secondary endpoint found liver fat normalization, defined as a liver fat content below 5% by MRI proton density fat fraction, in 61.0% of treated participants versus 5.7% with placebo. Liver fat is an imaging surrogate, not a clinical outcome; whether it translates into fewer cirrhosis events is precisely what LIVERAGE is designed to answer.

Total weight on a scale is a crude endpoint, because it sums fat mass, lean mass and fluid. Several survodutide analyses have tried to characterise the composition of the loss.

In a prespecified imaging analysis of SYNCHRONIZE-1 reported by the sponsor in June 2026, weight reduction at the 6.0 mg dose was accompanied by a relative reduction in visceral adipose tissue of about 34% and a relative reduction in liver fat of about 63% at week 76, compared with 24.5% for liver fat in the placebo group, with lean mass contributing only a small share of total weight lost. Visceral fat is the depot most tightly linked to cardiometabolic risk, so a loss concentrated there is mechanistically favourable. These figures come from sponsor communications and conference presentations; readers should look for the peer-reviewed body composition analysis before treating them as settled.

Blood pressure has also been examined. A post hoc analysis of the phase 2 obesity trial, published in Diabetes, Obesity and Metabolism in 2025, reported improvements in blood pressure in adults with obesity treated with survodutide. Post hoc analyses of a dose-finding trial cannot establish a blood pressure indication, but the direction of effect is consistent with what is seen across the incretin class.

On the glycemic side, SYNCHRONIZE-2 showed clinically meaningful HbA1c reduction alongside weight loss in people with type 2 diabetes, and a separate analysis published in 2026 reported improvements in biomarkers of beta-cell function and insulin sensitivity. This matters more for survodutide than for a pure GLP-1 agonist, because glucagon receptor agonism carries a theoretical risk of worsening glycemia. The observed improvement in glycemic measures is therefore evidence that the GLP-1 component adequately offsets the glucagon component at the doses studied.

The outcome that would matter most to patients, a reduction in cardiovascular events, remains unmeasured. SYNCHRONIZE-CVOT is the trial designed to address it, and until its results are published, any claim about cardiovascular benefit from survodutide is speculation.

The safety profile reported across survodutide trials is dominated by gastrointestinal adverse events, which is characteristic of GLP-1 receptor agonism and amplified here by rapid dose escalation.

In the phase 2 MASH trial, adverse events more frequent with survodutide than placebo included nausea (66% versus 23%), diarrhoea (49% versus 23%) and vomiting (41% versus 4%). Serious adverse events were comparable between groups, at 8% with survodutide and 7% with placebo. In the phase 2 obesity trial, gastrointestinal events affected roughly 75% of survodutide-treated participants versus about 42% on placebo, serious treatment-emergent adverse events were reported in 4% of survodutide participants versus 7% on placebo, and the investigators reported no unexpected safety concerns over 46 weeks.

The most informative tolerability number is discontinuation. In the phase 2 obesity trial, 24.6% of survodutide-treated participants stopped treatment because of adverse events, compared with 3.9% on placebo, and most of those discontinuations occurred during the rapid escalation phase. In phase 3 SYNCHRONIZE-1, with a longer titration, gastrointestinal adverse events were reported in 80.9% of the 3.6 mg group, 89.7% of the 6.0 mg group and 47.9% of the placebo group, generally mild to moderate in severity, and no deaths were reported.

Several points deserve emphasis for anyone reading these figures. Gastrointestinal events in this class are typically transient and escalation-related, but they are common enough that tolerability, not efficacy, is often the factor that determines whether someone can stay on treatment. Because survodutide also engages the glucagon receptor, heart rate and glycemic parameters are monitored closely in trials. And because survodutide has never been through a full regulatory safety review, there is no approved label enumerating contraindications, interactions or warnings. The absence of a label is not the absence of risk. For a broader discussion of tolerability in this drug class, see our article on GLP-1 side effects.

Disclaimer: adverse event rates above are drawn from controlled trials with medical supervision and protocol-defined escalation. They do not describe what would happen outside that setting, and this article contains no dosing or administration guidance of any kind.

As of October 2026, survodutide is not approved by the FDA, the EMA or any other regulatory agency, in any indication, in any country. It is an investigational compound available only through participation in a clinical trial.

Its most notable regulatory milestone is the Breakthrough Therapy designation granted by the US FDA in 2024 for the treatment of adults with non-cirrhotic MASH and moderate or advanced fibrosis, awarded on the strength of the phase 2 liver results. It is worth being precise about what this means. Breakthrough Therapy designation is a procedural mechanism that gives a sponsor more intensive FDA guidance and the possibility of a rolling or expedited review. It is a statement about unmet need and preliminary evidence, not a finding of efficacy or safety, and it does not lower the evidence bar for approval.

With SYNCHRONIZE-1, SYNCHRONIZE-2 and SYNCHRONIZE-MASLD now reported and SYNCHRONIZE-CVOT at or near completion, survodutide has reached the point where a regulatory submission in obesity becomes plausible. Boehringer Ingelheim had not publicly confirmed a filing date as of October 2026, and any timeline circulating online should be treated as an estimate rather than a commitment. In the MASH indication, the pivotal LIVERAGE trials read out later, so a liver-specific approval would necessarily follow an obesity approval.

Because survodutide is unapproved, material sold online under its name is not a pharmaceutical product. It is not manufactured under the conditions required for a medicine, is not subject to regulatory inspection for identity, purity, sterility or potency, and is typically labelled for laboratory research use only. The legal status of possessing or importing such material varies by jurisdiction. There is no legitimate supply chain for survodutide for personal use, and this guide does not point readers toward one.

If you are seeking treatment for obesity, type 2 diabetes or fatty liver disease, the appropriate routes are an approved medicine prescribed by a clinician or enrolment in a registered clinical trial. Discuss both with a qualified healthcare professional.

Survodutide competes in a field where the benchmark keeps moving. The table below sets out headline results from each molecule's pivotal obesity trial. Read it with care: these are separate trials with different populations, durations, comparators and statistical estimands, and indirect comparisons of this kind are among the least reliable forms of evidence.

On weight loss alone, survodutide does not lead this group. Its SYNCHRONIZE-1 result under the treatment-policy analysis is roughly comparable to or slightly below semaglutide in STEP 1, below tirzepatide in SURMOUNT-1, and well below retatrutide in TRIUMPH-1. Market analysts reacted to the phase 3 readouts accordingly, and it would be misleading to present survodutide as the most potent agent in development.

The comparison looks different when the endpoint is the liver. Survodutide has biopsy-based phase 2 data in MASH, Breakthrough Therapy designation in that indication, two dedicated phase 3 liver outcome trials and a mediation analysis suggesting a component of hepatic effect not explained by weight loss. Retatrutide also engages the glucagon receptor and has shown liver fat reductions, while semaglutide has phase 3 MASH data of its own; tirzepatide's mechanism does not include glucagon at all. Survodutide's plausible clinical niche is therefore liver disease and cardiometabolic risk rather than maximal weight reduction.

One structural difference is worth noting for anyone comparing mechanisms. Survodutide is the only compound in this table that pairs GLP-1 with glucagon and nothing else, which makes it the cleanest available test in humans of what glucagon receptor agonism contributes on its own. Retatrutide adds GIP to the same pair, so its results cannot isolate the glucagon contribution. That makes survodutide scientifically informative regardless of where it lands commercially.

Even with phase 3 data in hand, substantial uncertainty remains, and an honest guide should state it plainly.

Cardiovascular outcomes are unproven. SYNCHRONIZE-CVOT was designed as an event-driven safety trial with a five-component major adverse cardiac event endpoint, and its results had not been published as of October 2026. Glucagon receptor agonism raises legitimate questions about heart rate and blood pressure that only a large outcome trial can resolve.

Hard liver outcomes are years away. The existing MASH evidence rests on 48-week histology in 293 participants and on imaging surrogates in SYNCHRONIZE-MASLD. LIVERAGE follows participants for approximately seven years specifically because improvement on biopsy at one year does not guarantee fewer cases of cirrhosis, liver failure or transplant a decade later.

Durability and discontinuation are not characterised. The longest published survodutide trials run 76 weeks. Across this drug class, weight tends to be regained after treatment stops, and no published survodutide trial has followed participants through a withdrawal period long enough to quantify that.

Long-term safety is incomplete by definition. Rare adverse events, effects on bone and muscle over years, outcomes in pregnancy, and interactions in older adults or people with multiple conditions are not knowable from trials of this size and duration. This is true of every investigational compound and is the main reason regulators require post-marketing surveillance.

Comparative effectiveness is untested. There is no adequately powered head-to-head trial of survodutide against tirzepatide, retatrutide or semaglutide at their approved or investigational doses. The 16-week open-label semaglutide arm in the phase 2 diabetes trial does not fill that gap. Until a head-to-head trial exists, rankings between these molecules remain inference.

What can be said with reasonable confidence is narrow: in controlled trials, survodutide produced dose-dependent weight loss, improved glycemic measures in type 2 diabetes, reduced liver fat substantially, improved MASH histology at 48 weeks, and caused frequent gastrointestinal adverse events that led a meaningful minority of participants to stop treatment. Everything beyond that is still being measured.

Final disclaimer: this article is for educational purposes only and does not constitute medical advice. Survodutide is an investigational compound that is not approved for human use in any indication. It contains no dosing recommendation and no usage protocol. Consult a qualified healthcare professional before making any decision about your health, and note that the legal status of research compounds varies by jurisdiction.